PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 1730260-3 1992 Subsequently, infected T cells were selected on the basis of their ADA expression, by exposure to a combination of the toxic agent xylofuranosyl-adenine and the specific ADA inhibitor 2"-deoxycoformycin. Pentostatin 184-202 adenosine deaminase Homo sapiens 170-173 2033586-9 1991 In the presence of the potent ADA inhibitor 2"-deoxycoformycin, 6-halo-substituted ddPs failed to exert an in vitro antiretroviral effect. Pentostatin 44-62 adenosine deaminase Homo sapiens 30-33 1715181-4 1991 Deoxycoformycin (10(-4) M), an inhibitor of adenosine deaminase activity, prevented the increase in superoxide production associated with adenosine deaminase addition. Pentostatin 0-15 adenosine deaminase Homo sapiens 44-63 1715181-4 1991 Deoxycoformycin (10(-4) M), an inhibitor of adenosine deaminase activity, prevented the increase in superoxide production associated with adenosine deaminase addition. Pentostatin 0-15 adenosine deaminase Homo sapiens 138-157 2033591-7 1991 The anti-HIV activity of 1f and 1i was abolished when the ADA inhibitor, 2"-deoxycoformycin, was added to the test mixture. Pentostatin 73-91 adenosine deaminase Homo sapiens 58-61 1995064-5 1991 In medium supplemented with the adenosine deaminase inhibitor deoxycoformycin, the T cells with increased 5"-nucleotidase accumulated less nucleotides from exogenously added deoxyadenosine, or 9-beta-D-arabinofuranosyladenine, than did parental T lymphocytes. Pentostatin 62-77 adenosine deaminase Homo sapiens 32-51 1898656-4 1991 A similar accumulation was observed with both unstimulated and stimulated PMNs after the addition of deoxycoformycin (dCF, 1-100 microM), an inhibitor of adenosine deaminase. Pentostatin 101-116 adenosine deaminase Homo sapiens 154-173 1679757-2 1991 Three new purine nucleoside analogues, deoxycoformycin, fludarabine, and 2-chlorodeoxyadenosine, affect the normal function of the purine salvage pathway by inhibiting ADA or by acting as analogs of the ADA substrates. Pentostatin 39-54 adenosine deaminase Homo sapiens 168-171 1679757-2 1991 Three new purine nucleoside analogues, deoxycoformycin, fludarabine, and 2-chlorodeoxyadenosine, affect the normal function of the purine salvage pathway by inhibiting ADA or by acting as analogs of the ADA substrates. Pentostatin 39-54 adenosine deaminase Homo sapiens 203-206 1898656-4 1991 A similar accumulation was observed with both unstimulated and stimulated PMNs after the addition of deoxycoformycin (dCF, 1-100 microM), an inhibitor of adenosine deaminase. Pentostatin 118-121 adenosine deaminase Homo sapiens 154-173 2262486-7 1990 Future studies will (1) determine the optimal dose and schedule of cytosine arabinoside needed to exploit the increased Ara-CTP accumulation in T-cell blasts, (2) determine the efficacy of a new agent, deoxycoformycin, an inhibitor of adenosine deaminase, to exploit the biochemical phenotype of T-cell blasts, and (3) assess the ability of conjugated anti-T monoclonal antibodies to deliver a cytotoxic agent, thus exploiting unique antigenic determinants at the cell surface. Pentostatin 202-217 adenosine deaminase Homo sapiens 235-254 2357554-1 1990 The use of a relatively specific adenosine deaminase inhibitor, 2"-deoxycoformycin (1.0 microM), has revealed an active transport of adenosine into astrocytes in primary cultures. Pentostatin 64-82 adenosine deaminase Homo sapiens 33-52 2273300-0 1990 Combined effects of interferon and 2"-deoxycoformycin on 2",5"-oligoadenylate synthetase and adenosine deaminase in hairy cell and chronic lymphocytic leukemia cells. Pentostatin 35-53 adenosine deaminase Homo sapiens 93-112 2273300-1 1990 The combined effects of interferon (IFN) and 2"-deoxycoformycin (DCF) on 2",5"-oligoadenylate (2-5A) synthetase and adenosine deaminase (ADA) activity were examined in vitro in peripheral blood mononuclear cells from patients with hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL). Pentostatin 65-68 adenosine deaminase Homo sapiens 137-140 2273300-2 1990 In HCL cells, the effects of IFN and DCF on both OAS and ADA activity were strictly antagonistic. Pentostatin 37-40 adenosine deaminase Homo sapiens 57-60 2273300-4 1990 If OAS and ADA are important in the antitumor effects of IFN and DCF, our results suggest that combination therapy with IFN and DCF could be counterproductive. Pentostatin 65-68 adenosine deaminase Homo sapiens 11-14 2275794-0 1990 Structural and conformational analysis of pentostatin (2"-deoxycoformycin), a potent inhibitor of adenosine deaminase. Pentostatin 42-53 adenosine deaminase Homo sapiens 98-117 2275794-0 1990 Structural and conformational analysis of pentostatin (2"-deoxycoformycin), a potent inhibitor of adenosine deaminase. Pentostatin 55-73 adenosine deaminase Homo sapiens 98-117 2275794-1 1990 X-ray, NMR and molecular mechanics studies on pentostatin (C11H16N4O4), a potent inhibitor of the enzyme adenosine deaminase, have been carried out to study the structure and conformation. Pentostatin 46-57 adenosine deaminase Homo sapiens 105-124 2316512-4 1990 Furthermore, DCF and agents that differentiated HL-60 cells had opposing effects on adenosine deaminase and 2",5"-oligoadenylate synthetase activity. Pentostatin 13-16 adenosine deaminase Homo sapiens 84-103 2190792-5 1990 The antimetabolites consist of methotrexate, the pyrimidine and purine analogues, and pentostatin, an adenosine deaminase inhibitor and relative newcomer to the class. Pentostatin 86-97 adenosine deaminase Homo sapiens 102-121 2497184-7 1989 Analysis of 2"-deoxyadenosine-challenged cells showed that TJF-2 cells accumulated significant levels of deoxyadenosine triphosphate, whereas normal T cells did not unless they were also incubated with the ADA inhibitor deoxycoformycin. Pentostatin 220-235 adenosine deaminase Homo sapiens 206-209 2291566-9 1990 We are using immortalized stromal cell lines resistant to deoxycoformycin (dCF) to select transduced murine HSC containing human ADA in vitro. Pentostatin 75-78 adenosine deaminase Homo sapiens 129-132 2812252-4 1989 A relatively specific adenosine deaminase inhibitor, 2"-deoxycoformycin, was used in the present study. Pentostatin 53-71 adenosine deaminase Homo sapiens 22-41 2788175-7 1989 NH3 production derived only from the deamination of adenosine by the enzyme adenosine deaminase and was abolished by 0.4 microM 2"-deoxycoformycin, a specific inhibitor of adenosine deaminase. Pentostatin 128-146 adenosine deaminase Homo sapiens 172-191 2502523-4 1989 DCF potentiated the antiproliferative activity of Ara-A not only in T-cell lines with high adenosine deaminase (ADA) activity, but also in some other cell lines with low ADA activity. Pentostatin 0-3 adenosine deaminase Homo sapiens 91-110 2502523-4 1989 DCF potentiated the antiproliferative activity of Ara-A not only in T-cell lines with high adenosine deaminase (ADA) activity, but also in some other cell lines with low ADA activity. Pentostatin 0-3 adenosine deaminase Homo sapiens 112-115 2502523-4 1989 DCF potentiated the antiproliferative activity of Ara-A not only in T-cell lines with high adenosine deaminase (ADA) activity, but also in some other cell lines with low ADA activity. Pentostatin 0-3 adenosine deaminase Homo sapiens 170-173 2841534-7 1988 Special emphasis will be put on the clinical use of an ADA-inhibitor, deoxycoformycin. Pentostatin 70-85 adenosine deaminase Homo sapiens 55-58 2783731-1 1989 2"-Deoxycoformycin (pentostatin [dCF]), a potent inhibitor of adenosine deaminase (ADA), was administered in a biweekly low-dose (2 to 4 mg/m2) intravenous (IV) schedule to patients with advanced hairy cell leukemia. Pentostatin 0-18 adenosine deaminase Homo sapiens 62-81 2783731-1 1989 2"-Deoxycoformycin (pentostatin [dCF]), a potent inhibitor of adenosine deaminase (ADA), was administered in a biweekly low-dose (2 to 4 mg/m2) intravenous (IV) schedule to patients with advanced hairy cell leukemia. Pentostatin 0-18 adenosine deaminase Homo sapiens 83-86 2783731-1 1989 2"-Deoxycoformycin (pentostatin [dCF]), a potent inhibitor of adenosine deaminase (ADA), was administered in a biweekly low-dose (2 to 4 mg/m2) intravenous (IV) schedule to patients with advanced hairy cell leukemia. Pentostatin 20-31 adenosine deaminase Homo sapiens 62-81 2783731-1 1989 2"-Deoxycoformycin (pentostatin [dCF]), a potent inhibitor of adenosine deaminase (ADA), was administered in a biweekly low-dose (2 to 4 mg/m2) intravenous (IV) schedule to patients with advanced hairy cell leukemia. Pentostatin 20-31 adenosine deaminase Homo sapiens 83-86 2575348-2 1989 We now show that human monocytes are also highly sensitive in vitro to nanomolar concentrations of deoxyadenosine plus the ADA inhibitor deoxycoformycin, and to the ADA-resistant analogue 2-chlorodeoxyadenosine (CdA). Pentostatin 137-152 adenosine deaminase Homo sapiens 123-126 3263401-1 1988 2"-Deoxycoformycin, a potent inhibitor of adenosine deaminase, was administered to three patients with cutaneous T cell lymphoma refractory to multiple treatment modalities. Pentostatin 0-18 adenosine deaminase Homo sapiens 42-61 3260524-6 1988 These effects of ADA depended on its enzymatic activity as they could be blocked by preincubation with DCF. Pentostatin 103-106 adenosine deaminase Homo sapiens 17-20 3258602-2 1988 However, these dideoxynucleosides may be catabolized by human T cells, even when adenosine deaminase is inhibited by deoxycoformycin. Pentostatin 117-132 adenosine deaminase Homo sapiens 81-100 3342099-4 1988 If ADA activity was blocked by 2"-deoxycoformycin (dCF, 5 microM), a tight-binding inhibitor of ADA, most of the Ado (96%) was incorporated into adenine nucleotides, whereas if Ado kinase activity was blocked with 5-iodotubercidin (10 microM), Ado was mainly (95%) metabolized into hypoxanthine. Pentostatin 31-49 adenosine deaminase Homo sapiens 3-6 3342099-4 1988 If ADA activity was blocked by 2"-deoxycoformycin (dCF, 5 microM), a tight-binding inhibitor of ADA, most of the Ado (96%) was incorporated into adenine nucleotides, whereas if Ado kinase activity was blocked with 5-iodotubercidin (10 microM), Ado was mainly (95%) metabolized into hypoxanthine. Pentostatin 31-49 adenosine deaminase Homo sapiens 96-99 3342099-4 1988 If ADA activity was blocked by 2"-deoxycoformycin (dCF, 5 microM), a tight-binding inhibitor of ADA, most of the Ado (96%) was incorporated into adenine nucleotides, whereas if Ado kinase activity was blocked with 5-iodotubercidin (10 microM), Ado was mainly (95%) metabolized into hypoxanthine. Pentostatin 51-54 adenosine deaminase Homo sapiens 3-6 3342099-4 1988 If ADA activity was blocked by 2"-deoxycoformycin (dCF, 5 microM), a tight-binding inhibitor of ADA, most of the Ado (96%) was incorporated into adenine nucleotides, whereas if Ado kinase activity was blocked with 5-iodotubercidin (10 microM), Ado was mainly (95%) metabolized into hypoxanthine. Pentostatin 51-54 adenosine deaminase Homo sapiens 96-99 3257147-0 1988 Opposite effects of recombinant interferon-alpha A and deoxycoformycin on adenosine deaminase activity in the Daudi B lymphoblastoid cell line. Pentostatin 55-70 adenosine deaminase Homo sapiens 74-93 3257147-1 1988 Interferon-alpha and the adenosine deaminase (ADA) inhibitor deoxycoformycin (dCF) have each been shown to be efficacious in the treatment of some lymphoid malignancies and to have potent antiproliferative activities in vitro. Pentostatin 61-76 adenosine deaminase Homo sapiens 46-49 3257147-1 1988 Interferon-alpha and the adenosine deaminase (ADA) inhibitor deoxycoformycin (dCF) have each been shown to be efficacious in the treatment of some lymphoid malignancies and to have potent antiproliferative activities in vitro. Pentostatin 78-81 adenosine deaminase Homo sapiens 25-44 3257147-1 1988 Interferon-alpha and the adenosine deaminase (ADA) inhibitor deoxycoformycin (dCF) have each been shown to be efficacious in the treatment of some lymphoid malignancies and to have potent antiproliferative activities in vitro. Pentostatin 78-81 adenosine deaminase Homo sapiens 46-49 3257147-3 1988 Treatment of Daudi cells for three to four days with doses of rIFN-alpha A that were growth inhibitory was unexpectedly found to increase the level of ADA activity per cell two- to threefold and therefore to prevent the inhibition of ADA by limiting concentrations of dCF. Pentostatin 268-271 adenosine deaminase Homo sapiens 151-154 3257147-3 1988 Treatment of Daudi cells for three to four days with doses of rIFN-alpha A that were growth inhibitory was unexpectedly found to increase the level of ADA activity per cell two- to threefold and therefore to prevent the inhibition of ADA by limiting concentrations of dCF. Pentostatin 268-271 adenosine deaminase Homo sapiens 234-237 3257147-4 1988 However, the opposite effects of dCF and rIFN-alpha A on ADA activity did not lead to antagonistic effects on growth inhibition. Pentostatin 33-36 adenosine deaminase Homo sapiens 57-60 3257147-5 1988 The higher concentrations of dCF (with deoxyadenosine) necessary for appreciable growth inhibition could inhibit the increased ADA activity in rIFN-alpha A-treated cells, thus resulting in additive antiproliferative effects. Pentostatin 29-32 adenosine deaminase Homo sapiens 127-130 3257147-1 1988 Interferon-alpha and the adenosine deaminase (ADA) inhibitor deoxycoformycin (dCF) have each been shown to be efficacious in the treatment of some lymphoid malignancies and to have potent antiproliferative activities in vitro. Pentostatin 61-76 adenosine deaminase Homo sapiens 25-44 2890401-1 1987 The adenosine deaminase inhibitor deoxycoformycin was used in low doses to treat 19 patients with clinically aggressive T cell malignancy with a mature membrane phenotype. Pentostatin 34-49 adenosine deaminase Homo sapiens 4-23 3332090-2 1987 Pentostatin is an inhibitor of adenosine deaminase, an enzyme that is important for purine metabolism, but more than one mechanism may be involved in its cytotoxic action. Pentostatin 0-11 adenosine deaminase Homo sapiens 31-50 3829699-4 1987 A single topical dose with as low as 0.1% 2"-deoxycoformycin (dCF), an ADA inhibitor possessing immunosuppressive activity, was capable of totally inhibiting the corneal ADA activity. Pentostatin 42-60 adenosine deaminase Homo sapiens 71-74 3829699-4 1987 A single topical dose with as low as 0.1% 2"-deoxycoformycin (dCF), an ADA inhibitor possessing immunosuppressive activity, was capable of totally inhibiting the corneal ADA activity. Pentostatin 42-60 adenosine deaminase Homo sapiens 170-173 3829699-4 1987 A single topical dose with as low as 0.1% 2"-deoxycoformycin (dCF), an ADA inhibitor possessing immunosuppressive activity, was capable of totally inhibiting the corneal ADA activity. Pentostatin 62-65 adenosine deaminase Homo sapiens 71-74 3829699-4 1987 A single topical dose with as low as 0.1% 2"-deoxycoformycin (dCF), an ADA inhibitor possessing immunosuppressive activity, was capable of totally inhibiting the corneal ADA activity. Pentostatin 62-65 adenosine deaminase Homo sapiens 170-173 3829699-5 1987 Titration of the free dCF in the cornea following a single topical dose of 0.25% dCF indicated that enough dCF remained in the cornea 24 hrs after instillation to totally inhibit all corneal ADA plus 66 units of additional enzyme. Pentostatin 81-84 adenosine deaminase Homo sapiens 191-194 3829699-5 1987 Titration of the free dCF in the cornea following a single topical dose of 0.25% dCF indicated that enough dCF remained in the cornea 24 hrs after instillation to totally inhibit all corneal ADA plus 66 units of additional enzyme. Pentostatin 81-84 adenosine deaminase Homo sapiens 191-194 3488805-1 1986 Pentostatin (dCF), an inhibitor of adenosine deaminase, has shown activity in the treatment of several lymphoid malignancies, even in the earliest phase I trials. Pentostatin 0-11 adenosine deaminase Homo sapiens 35-54 3488805-1 1986 Pentostatin (dCF), an inhibitor of adenosine deaminase, has shown activity in the treatment of several lymphoid malignancies, even in the earliest phase I trials. Pentostatin 13-16 adenosine deaminase Homo sapiens 35-54 2939873-1 1986 Two elderly patients with prolymphocytic leukaemia (PLL) of T helper phenotype were treated with the adenosine deaminase inhibitor--deoxycoformycin--and achieved remission. Pentostatin 132-147 adenosine deaminase Homo sapiens 101-120 3011239-2 1986 Recent studies have shown that hairy cell leukemia (HCL) may respond to treatment with the ADA inhibitor, 2-deoxycoformycin. Pentostatin 106-123 adenosine deaminase Homo sapiens 91-94 3486414-2 1986 Cells that incorporate the gene can be selected by growth in the presence of low concentrations of the ADA inhibitor 2"-deoxycoformycin with cytotoxic concentrations of adenosine or its analogue 9-beta-D-xylofuranosyl adenine. Pentostatin 117-135 adenosine deaminase Homo sapiens 103-106 3872599-3 1985 Adult AKR/J mice were treated with 10 micrograms/g or 100 micrograms/g 2"-deoxycoformycin, an adenosine deaminase inhibitor with chemotherapeutic potential. Pentostatin 71-89 adenosine deaminase Homo sapiens 94-113 3486057-1 1986 The metabolic changes induced by the deoxycoformycin inhibition of adenosine deaminase were studied in human erythrocytes incubated with nucleosides. Pentostatin 37-52 adenosine deaminase Homo sapiens 67-86 2433905-5 1986 The enzyme-inhibitor complex between adenosine deaminase and 2"-chloropentostatin was much more rapidly dissociable than the complex with pentostatin. Pentostatin 70-81 adenosine deaminase Homo sapiens 37-56 2433905-6 1986 The complex between adenosine deaminase and 2"-chloropentostatin dissociated with a half-life of approximately 3 hr, compared with 68 hr for the complex between adenosine deaminase and pentostatin. Pentostatin 53-64 adenosine deaminase Homo sapiens 20-39 2433905-6 1986 The complex between adenosine deaminase and 2"-chloropentostatin dissociated with a half-life of approximately 3 hr, compared with 68 hr for the complex between adenosine deaminase and pentostatin. Pentostatin 53-64 adenosine deaminase Homo sapiens 161-180 3875570-10 1985 In addition, the antiproliferative effect of both core compounds and their corresponding nucleosides could be potentiated by the addition of the adenosine deaminase inhibitor, deoxycoformycin. Pentostatin 176-191 adenosine deaminase Homo sapiens 145-164 3873908-0 1985 Adenosine deaminase gene amplification in deoxycoformycin-resistant mammalian cells. Pentostatin 42-57 adenosine deaminase Homo sapiens 0-19 6424986-2 1984 Only 2"-deoxycoformycin (dCF) completely inhibited ADA in T and B cells at concentrations in excess of 5 microM. Pentostatin 5-23 adenosine deaminase Homo sapiens 51-54 2579098-1 1985 Deoxyadenosine has been implicated as the toxic metabolite causing profound lymphopenia in immunodeficient children with a genetic deficiency of adenosine deaminase (ADA), and in adults treated with the potent ADA inhibitor deoxycoformycin. Pentostatin 224-239 adenosine deaminase Homo sapiens 210-213 2981904-6 1985 The application of 2"-deoxycoformycin, a specific inhibitor of adenosine deaminase, and the potential usefulness of two other enzymes as targets for treatment with selective agents is discussed. Pentostatin 19-37 adenosine deaminase Homo sapiens 63-82 3881043-2 1985 Production of labeled inosine and hypoxanthine from adenosine was considerably lower in adenosine deaminase (ADA)-deficient cells than in normal cells and virtually eliminated in normal cells by the presence of 1 microM deoxycoformycin (a potent ADA inhibitor), suggesting that labeled inosine and hypoxanthine production requires ADA activity. Pentostatin 220-235 adenosine deaminase Homo sapiens 88-107 3881043-2 1985 Production of labeled inosine and hypoxanthine from adenosine was considerably lower in adenosine deaminase (ADA)-deficient cells than in normal cells and virtually eliminated in normal cells by the presence of 1 microM deoxycoformycin (a potent ADA inhibitor), suggesting that labeled inosine and hypoxanthine production requires ADA activity. Pentostatin 220-235 adenosine deaminase Homo sapiens 109-112 3881043-2 1985 Production of labeled inosine and hypoxanthine from adenosine was considerably lower in adenosine deaminase (ADA)-deficient cells than in normal cells and virtually eliminated in normal cells by the presence of 1 microM deoxycoformycin (a potent ADA inhibitor), suggesting that labeled inosine and hypoxanthine production requires ADA activity. Pentostatin 220-235 adenosine deaminase Homo sapiens 246-249 3881043-2 1985 Production of labeled inosine and hypoxanthine from adenosine was considerably lower in adenosine deaminase (ADA)-deficient cells than in normal cells and virtually eliminated in normal cells by the presence of 1 microM deoxycoformycin (a potent ADA inhibitor), suggesting that labeled inosine and hypoxanthine production requires ADA activity. Pentostatin 220-235 adenosine deaminase Homo sapiens 246-249 3874406-0 1985 Effects of adenosine deaminase inhibitor 2"-deoxycoformycin on the repair and expression of potentially lethal damage sensitive to beta-araA. Pentostatin 41-59 adenosine deaminase Homo sapiens 11-30 6334686-2 1984 It was found that in the presence of deoxycoformycin, an inhibitor of adenosine deaminase, deoxyadenosine was the only product of deoxy-ATP catabolism. Pentostatin 37-52 adenosine deaminase Homo sapiens 70-89 6334522-2 1984 The assay of residual adenosine deaminase (ADA) activity was used as a sensitive measure of the transport of deoxycoformycin (dCF) into human erythrocytes. Pentostatin 109-124 adenosine deaminase Homo sapiens 22-41 6334522-2 1984 The assay of residual adenosine deaminase (ADA) activity was used as a sensitive measure of the transport of deoxycoformycin (dCF) into human erythrocytes. Pentostatin 109-124 adenosine deaminase Homo sapiens 43-46 6334522-2 1984 The assay of residual adenosine deaminase (ADA) activity was used as a sensitive measure of the transport of deoxycoformycin (dCF) into human erythrocytes. Pentostatin 126-129 adenosine deaminase Homo sapiens 22-41 6334522-2 1984 The assay of residual adenosine deaminase (ADA) activity was used as a sensitive measure of the transport of deoxycoformycin (dCF) into human erythrocytes. Pentostatin 126-129 adenosine deaminase Homo sapiens 43-46 6334522-3 1984 Contrary to prior reports from this laboratory, the inactivation of intraerythrocytic ADA by dCF was linear rather than log-linear, with time. Pentostatin 93-96 adenosine deaminase Homo sapiens 86-89 6236916-2 1984 On this basis, patients with T cell malignancies have been treated with the ADA inhibitor, deoxycoformycin. Pentostatin 91-106 adenosine deaminase Homo sapiens 76-79 6204981-2 1984 The biochemical and metabolic effects of deoxycoformycin, a potent inhibitor of adenosine deaminase, were investigated using two human T lymphoblastoid cell lines. Pentostatin 41-56 adenosine deaminase Homo sapiens 80-99 6610485-1 1984 The biochemical mechanism of lymphocyte dysfunction with adenosine deaminase deficiency has been investigated using cultured phytohemagglutinin stimulated normal peripheral blood lymphocytes and the adenosine deaminase (ADA) inhibitor 2"-deoxycoformycin. Pentostatin 235-253 adenosine deaminase Homo sapiens 57-76 6610419-1 1984 An analytical method for determination of 2"-deoxycoformycin (2"-DCF) concentrations in plasma and urine was developed based upon a modification of adenosine deaminase (ADA) inhibition assays described in the literature. Pentostatin 42-60 adenosine deaminase Homo sapiens 169-172 6610419-1 1984 An analytical method for determination of 2"-deoxycoformycin (2"-DCF) concentrations in plasma and urine was developed based upon a modification of adenosine deaminase (ADA) inhibition assays described in the literature. Pentostatin 62-68 adenosine deaminase Homo sapiens 148-167 6610419-1 1984 An analytical method for determination of 2"-deoxycoformycin (2"-DCF) concentrations in plasma and urine was developed based upon a modification of adenosine deaminase (ADA) inhibition assays described in the literature. Pentostatin 62-68 adenosine deaminase Homo sapiens 169-172 6610419-6 1984 Quantitation of 2"-DCF in patient samples is accomplished by an ADA inhibition titration technique in which the spectrophotometrically determined absorbance change is related to the two independent variables, the concentration of 2"-DCF in the standards and the relative time of the analysis. Pentostatin 16-22 adenosine deaminase Homo sapiens 64-67 6424986-2 1984 Only 2"-deoxycoformycin (dCF) completely inhibited ADA in T and B cells at concentrations in excess of 5 microM. Pentostatin 25-28 adenosine deaminase Homo sapiens 51-54 6609525-0 1984 Adenosine deaminase in malaria infection: effect of 2"-deoxycoformycin in vivo. Pentostatin 52-70 adenosine deaminase Homo sapiens 0-19 6609531-0 1984 Deoxycoformycin resistant mammalian cells that overproduce adenosine deaminase. Pentostatin 0-15 adenosine deaminase Homo sapiens 59-78 6311934-9 1983 Inactivation of ADA with DCF abrogated the enhancement of superoxide anion generation. Pentostatin 25-28 adenosine deaminase Homo sapiens 16-19 6607471-0 1984 Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2"-deoxycoformycin. Pentostatin 121-139 adenosine deaminase Homo sapiens 91-110 6414755-6 1983 Defibrination before nucleotide extraction of mononuclear cells from a patient with T-cell leukaemic/lymphoma treated with the ADA inhibitor deoxycoformycin enabled the demonstration of grossly raised deoxy-ATP levels relative to deoxy-ADP levels (ratio 16.1:1), associated with severe ATP depletion. Pentostatin 141-156 adenosine deaminase Homo sapiens 127-130 6600401-1 1983 We have investigated the use of 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), in the treatment of 4 patients with advanced mycosis fungoides (MF). Pentostatin 32-50 adenosine deaminase Homo sapiens 80-99 6601986-1 1983 A patient with refractory T-cell acute lymphoblastic leukemia was treated with eight courses of the adenosine deaminase inhibitor, 2"-deoxycoformycin (dCF), over a 5-month period. Pentostatin 131-149 adenosine deaminase Homo sapiens 100-119 6601986-1 1983 A patient with refractory T-cell acute lymphoblastic leukemia was treated with eight courses of the adenosine deaminase inhibitor, 2"-deoxycoformycin (dCF), over a 5-month period. Pentostatin 151-154 adenosine deaminase Homo sapiens 100-119 6303563-3 1983 The minimal ADA activity in DHL-9 extracts, 0.028 nmol/min/mg protein, was less than 50% of the activity in two B-lymphoblastoid cell lines from ADA-deficient patients and was resistant to the potent ADA inhibitor deoxycoformycin. Pentostatin 214-229 adenosine deaminase Homo sapiens 12-15 6600401-1 1983 We have investigated the use of 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), in the treatment of 4 patients with advanced mycosis fungoides (MF). Pentostatin 32-50 adenosine deaminase Homo sapiens 101-104 6600401-1 1983 We have investigated the use of 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), in the treatment of 4 patients with advanced mycosis fungoides (MF). Pentostatin 52-55 adenosine deaminase Homo sapiens 80-99 6600401-1 1983 We have investigated the use of 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), in the treatment of 4 patients with advanced mycosis fungoides (MF). Pentostatin 52-55 adenosine deaminase Homo sapiens 101-104 6283540-1 1982 Loss of ATP accompanying accumulation of dATP has recently been reported to occur in the erythrocytes and lymphoblasts of patients with T lymphocytic leukemia during treatment with deoxycoformycin, an inhibitor of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) that causes the accumulation of deoxyadenosine. Pentostatin 181-196 adenosine deaminase Homo sapiens 214-233 6289941-1 1982 Leukemic cells incubated in vitro with 2"-deoxyadenosine (dAdo) plus an inhibitor of adenosine deaminase, 2"-deoxy-coformycin (DCF), show different metabolic responses depending on the histologic and immunologic type of the leukemia. Pentostatin 106-125 adenosine deaminase Homo sapiens 85-104 6980706-1 1982 It has been suggested that, by inhibiting the adenosine deaminase (ADA)-mediated catabolism of 9-beta-D-arabinofuranosyladenine (ara-A), 2"-deoxycoformycin (DCF) would increase the half-life (t1/2) of ara-A, a compound with known antileukemic activity. Pentostatin 137-155 adenosine deaminase Homo sapiens 46-65 6980706-1 1982 It has been suggested that, by inhibiting the adenosine deaminase (ADA)-mediated catabolism of 9-beta-D-arabinofuranosyladenine (ara-A), 2"-deoxycoformycin (DCF) would increase the half-life (t1/2) of ara-A, a compound with known antileukemic activity. Pentostatin 137-155 adenosine deaminase Homo sapiens 67-70 6980706-1 1982 It has been suggested that, by inhibiting the adenosine deaminase (ADA)-mediated catabolism of 9-beta-D-arabinofuranosyladenine (ara-A), 2"-deoxycoformycin (DCF) would increase the half-life (t1/2) of ara-A, a compound with known antileukemic activity. Pentostatin 157-160 adenosine deaminase Homo sapiens 46-65 6980706-1 1982 It has been suggested that, by inhibiting the adenosine deaminase (ADA)-mediated catabolism of 9-beta-D-arabinofuranosyladenine (ara-A), 2"-deoxycoformycin (DCF) would increase the half-life (t1/2) of ara-A, a compound with known antileukemic activity. Pentostatin 157-160 adenosine deaminase Homo sapiens 67-70 6980706-9 1982 These data confirm that the kinetics of ara-A catabolism can be altered by inhibition of ADA and suggest that more than one dose of DCF may be necessary for complete inhibition of the enzyme and optimal pharmacological modulation of ara-A. Pentostatin 132-135 adenosine deaminase Homo sapiens 89-92 6981855-0 1982 Isolation of deoxycoformycin-resistant cells with increased levels of adenosine deaminase. Pentostatin 13-28 adenosine deaminase Homo sapiens 70-89 6981855-1 1982 Deoxycoformycin (dCF) is a specific inhibitor of adenosine deaminase (ADA). Pentostatin 0-15 adenosine deaminase Homo sapiens 49-68 6981855-1 1982 Deoxycoformycin (dCF) is a specific inhibitor of adenosine deaminase (ADA). Pentostatin 17-20 adenosine deaminase Homo sapiens 49-68 6981855-5 1982 Initially, dCF-resistant cell lines have 3-10 times the level of adenosine deaminase when compared to sensitive parental cells. Pentostatin 11-14 adenosine deaminase Homo sapiens 65-84 6283540-1 1982 Loss of ATP accompanying accumulation of dATP has recently been reported to occur in the erythrocytes and lymphoblasts of patients with T lymphocytic leukemia during treatment with deoxycoformycin, an inhibitor of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) that causes the accumulation of deoxyadenosine. Pentostatin 181-196 adenosine deaminase Homo sapiens 235-259 6263381-1 1981 Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA). Pentostatin 0-15 adenosine deaminase Homo sapiens 41-60 6977672-1 1982 2"-Deoxycoformycin (DCF) is an inhibitor of the enzyme adenosine deaminase (ADA) and has shown promise as an antileukemia agent. Pentostatin 0-18 adenosine deaminase Homo sapiens 55-74 6977672-1 1982 2"-Deoxycoformycin (DCF) is an inhibitor of the enzyme adenosine deaminase (ADA) and has shown promise as an antileukemia agent. Pentostatin 0-18 adenosine deaminase Homo sapiens 76-79 6977672-1 1982 2"-Deoxycoformycin (DCF) is an inhibitor of the enzyme adenosine deaminase (ADA) and has shown promise as an antileukemia agent. Pentostatin 20-23 adenosine deaminase Homo sapiens 55-74 6977672-1 1982 2"-Deoxycoformycin (DCF) is an inhibitor of the enzyme adenosine deaminase (ADA) and has shown promise as an antileukemia agent. Pentostatin 20-23 adenosine deaminase Homo sapiens 76-79 6977170-4 1982 Deoxycoformycin, an adenosine analog which is a potent inhibitor of adenosine deaminase, has shown moderate activity in acute leukemia patients in phase I trials, and has the potential to produce synergistic antitumor toxicity when used with arabinofuranosyladenine. Pentostatin 0-15 adenosine deaminase Homo sapiens 68-87 6972800-1 1981 The in vitro effects of deoxyadenosine and an adenosine deaminase inhibitor, deoxycoformycin, on the synthesis of DNA and the metabolism of purines were investigated in human leukemic T-cells. Pentostatin 77-92 adenosine deaminase Homo sapiens 46-65 6263381-1 1981 Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA). Pentostatin 0-15 adenosine deaminase Homo sapiens 62-65 6263381-1 1981 Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA). Pentostatin 17-20 adenosine deaminase Homo sapiens 41-60 6263381-1 1981 Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA). Pentostatin 17-20 adenosine deaminase Homo sapiens 62-65 6967747-1 1980 We have treated a patient with refractory T-cell acute lymphoblastic leukemia with 2"-deoxycoformycin, a potent inhibitor of the enzyme adenosine deaminase. Pentostatin 83-101 adenosine deaminase Homo sapiens 136-155 6785321-5 1981 Thy-ALL blasts, however, appear to be selectively and exquisitely susceptible to inhibition of ADA by the drug deoxycoformycin, which has now been used sucessfully in a number of other wise resistant patients with Thy-ALL to obtain a complete remission. Pentostatin 111-126 adenosine deaminase Homo sapiens 95-98 6975188-1 1981 Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I--II evaluation. Pentostatin 0-15 adenosine deaminase Homo sapiens 54-73 6975188-1 1981 Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I--II evaluation. Pentostatin 0-15 adenosine deaminase Homo sapiens 75-78 6975188-1 1981 Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I--II evaluation. Pentostatin 17-20 adenosine deaminase Homo sapiens 54-73 6975188-1 1981 Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I--II evaluation. Pentostatin 17-20 adenosine deaminase Homo sapiens 75-78 7018725-2 1981 2"-deoxycoformycin (2"-dCF) is a powerful inhibitor of adenosine deaminase (ADA), an enzyme found in high concentrations in lymphoid tissue. Pentostatin 0-18 adenosine deaminase Homo sapiens 55-74 7018725-2 1981 2"-deoxycoformycin (2"-dCF) is a powerful inhibitor of adenosine deaminase (ADA), an enzyme found in high concentrations in lymphoid tissue. Pentostatin 0-18 adenosine deaminase Homo sapiens 76-79 7018725-2 1981 2"-deoxycoformycin (2"-dCF) is a powerful inhibitor of adenosine deaminase (ADA), an enzyme found in high concentrations in lymphoid tissue. Pentostatin 20-26 adenosine deaminase Homo sapiens 55-74 7018725-2 1981 2"-deoxycoformycin (2"-dCF) is a powerful inhibitor of adenosine deaminase (ADA), an enzyme found in high concentrations in lymphoid tissue. Pentostatin 20-26 adenosine deaminase Homo sapiens 76-79 6969403-2 1980 We have administered 2"-deoxycoformycin, a potent inhibitor of adenosine deaminase, to a patient with a lymphoproliferative malignancy. Pentostatin 21-39 adenosine deaminase Homo sapiens 63-82 6970630-0 1980 The clinical pharmacology of the adenosine deaminase inhibitor 2"-deoxycoformycin. Pentostatin 63-81 adenosine deaminase Homo sapiens 33-52 6105339-1 1980 Two patients with relapsed acute lymphoblastic leukaemia of thymic phenotype (Thy-ALL) resistant to all conventional chemotherapy achieved complete remission when treated with 2"-deoxycoformycin, a selectively lymphocytotoxic compound that acts by inhibition of the enzyme adenosine deaminase. Pentostatin 176-194 adenosine deaminase Homo sapiens 273-292 6970630-1 1980 2"-deoxycoformycin (2"-dCF; Pentostatin), a stoichiometric inhibitor of mammalian adenosine deaminase (ado deaminase), exhibits immunosuppressive and antilymphocytic activity in animal test systems. Pentostatin 0-18 adenosine deaminase Homo sapiens 82-101 6970630-1 1980 2"-deoxycoformycin (2"-dCF; Pentostatin), a stoichiometric inhibitor of mammalian adenosine deaminase (ado deaminase), exhibits immunosuppressive and antilymphocytic activity in animal test systems. Pentostatin 20-26 adenosine deaminase Homo sapiens 82-101 6970630-1 1980 2"-deoxycoformycin (2"-dCF; Pentostatin), a stoichiometric inhibitor of mammalian adenosine deaminase (ado deaminase), exhibits immunosuppressive and antilymphocytic activity in animal test systems. Pentostatin 28-39 adenosine deaminase Homo sapiens 82-101 119038-2 1979 Inhibition was greatly enhanced by an adenosine deaminase inhibitor (2-deoxycoformycin) in concentrations down to 10 ng/ml. Pentostatin 69-86 adenosine deaminase Homo sapiens 38-57 18721115-3 2008 OBJECTIVE: To identify the role of pentostatin, a specific inhibitor of adenosine deaminase (ADA), in the treatment of CLL. Pentostatin 35-46 adenosine deaminase Homo sapiens 72-91 280160-0 1977 Inhibition of adenosine deaminase by co-vidarabine and its effect on the metabolic disposition of adenine arabinoside (vidarabine). Pentostatin 37-50 adenosine deaminase Homo sapiens 14-33 26659614-1 2016 The treatment with deoxycoformycin, a strong adenosine deaminase inhibitor, in combination with deoxyadenosine, causes apoptotic cell death of two human neuroblastoma cell lines, SH-SY5Y and LAN5. Pentostatin 19-34 adenosine deaminase Homo sapiens 45-64 191546-4 1977 These same tests were repeated in the presence of a potent inhibitor of adenosine deaminase, R-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo-4,5-d)-(1,3)-diazepin-8-ol (co-vidarabine, co-ara-A). Pentostatin 191-204 adenosine deaminase Homo sapiens 72-91 33948356-8 2021 The administration of naringin and pentostatin, inhibitors for adenosine deaminase (ADA), enzyme responsible for cordycepin degradation, did not show a synergistic effect in MPNST cells treated with cordycepin. Pentostatin 35-46 adenosine deaminase Homo sapiens 84-87 25447764-5 2015 We have previously demonstrated that the combination of deoxycoformycin, a strong adenosine deaminase inhibitor, and deoxyadenosine is toxic for a human astrocytoma cell line. Pentostatin 56-71 adenosine deaminase Homo sapiens 82-101 22353632-3 2012 We have mimicked an adenosine deaminase-deficient situation by incubating a human astrocytoma cell line in the presence of deoxycoformycin, a strong adenosine deaminase inhibitor, and deoxyadenosine, which accumulates in vivo when the enzyme is deficient, and have monitored the effect of the combination on cell viability, mitochondrial functions, and other metabolic features. Pentostatin 123-138 adenosine deaminase Homo sapiens 20-39 22353632-3 2012 We have mimicked an adenosine deaminase-deficient situation by incubating a human astrocytoma cell line in the presence of deoxycoformycin, a strong adenosine deaminase inhibitor, and deoxyadenosine, which accumulates in vivo when the enzyme is deficient, and have monitored the effect of the combination on cell viability, mitochondrial functions, and other metabolic features. Pentostatin 123-138 adenosine deaminase Homo sapiens 149-168 21463108-3 2011 dCF is a potent inhibitor of adenosine deaminase (ADA), and treatment results in the accumulation of deoxyadenosine (dAdo) and adenosine (Ado) in the plasma. Pentostatin 0-3 adenosine deaminase Homo sapiens 29-48 21463108-3 2011 dCF is a potent inhibitor of adenosine deaminase (ADA), and treatment results in the accumulation of deoxyadenosine (dAdo) and adenosine (Ado) in the plasma. Pentostatin 0-3 adenosine deaminase Homo sapiens 50-53 19728741-14 2009 Compared to malarial ADA complexes with adenosine or deoxycoformycin, 5"-methylthioribosyl groups are rotated 130 degrees . Pentostatin 53-68 adenosine deaminase Homo sapiens 21-24 18602399-7 2008 We now report crystal structures of Plasmodium vivax ADA in complex with adenosine, guanosine, and the picomolar inhibitor 2"-deoxycoformycin. Pentostatin 123-141 adenosine deaminase Homo sapiens 53-56 18721115-3 2008 OBJECTIVE: To identify the role of pentostatin, a specific inhibitor of adenosine deaminase (ADA), in the treatment of CLL. Pentostatin 35-46 adenosine deaminase Homo sapiens 93-96 15837980-3 2005 Pentostatin, a potent inhibitor of adenosine deaminase, induces lymphocyte apoptosis and may be useful in the treatment of this condition. Pentostatin 0-11 adenosine deaminase Homo sapiens 35-54 17097637-4 2007 These effects were potentiated by co-incubation with homocysteine or adenosine deaminase inhibitor, pentostatin, and were mimicked by inhibition of AdoHcy hydrolase by adenosine-2",3"-dialdehyde (Adox). Pentostatin 100-111 adenosine deaminase Homo sapiens 69-88 16549110-2 2006 Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. Pentostatin 12-23 adenosine deaminase Homo sapiens 61-80 16549110-2 2006 Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. Pentostatin 12-23 adenosine deaminase Homo sapiens 82-85 16549110-4 2006 Early clinical trials with pentostatin used high doses for acute lymphoblastic leukemias, which were characterized by high levels of ADA. Pentostatin 27-38 adenosine deaminase Homo sapiens 133-136 15135110-9 2004 The deamination of CdA was completely inhibited by deoxycoformycin, which clearly demonstrates that CdA is a substrate for adenosine deaminase. Pentostatin 51-66 adenosine deaminase Homo sapiens 123-142 15752710-4 2005 Here, we show that deoxyadenosine itself is also a potent activator of dCK if its deamination was prevented by the adenosine deaminase inhibitor deoxycoformycin. Pentostatin 145-160 adenosine deaminase Homo sapiens 115-134 14760072-1 2004 PURPOSE AND EXPERIMENTAL DESIGN: dCF (2"-deoxycoformycin) is a potent inhibitor of ADA (adenosine deaminase), an enzyme regulating intra- and extracellular concentrations of purine metabolites. Pentostatin 33-36 adenosine deaminase Homo sapiens 83-86 14760072-1 2004 PURPOSE AND EXPERIMENTAL DESIGN: dCF (2"-deoxycoformycin) is a potent inhibitor of ADA (adenosine deaminase), an enzyme regulating intra- and extracellular concentrations of purine metabolites. Pentostatin 33-36 adenosine deaminase Homo sapiens 88-107 14760072-1 2004 PURPOSE AND EXPERIMENTAL DESIGN: dCF (2"-deoxycoformycin) is a potent inhibitor of ADA (adenosine deaminase), an enzyme regulating intra- and extracellular concentrations of purine metabolites. Pentostatin 38-56 adenosine deaminase Homo sapiens 83-86 14760072-1 2004 PURPOSE AND EXPERIMENTAL DESIGN: dCF (2"-deoxycoformycin) is a potent inhibitor of ADA (adenosine deaminase), an enzyme regulating intra- and extracellular concentrations of purine metabolites. Pentostatin 38-56 adenosine deaminase Homo sapiens 88-107 14760072-3 2004 Once the surface expression of CD26 and ADA in a panel of cell lines and primary samples of T-cell leukemia/lymphoma was defined, we correlated this expression with the antiproliferative and apoptotic effect of dCF. Pentostatin 211-214 adenosine deaminase Homo sapiens 40-43 12643924-1 2003 We searched for non-nucleoside inhibitors of adenosine deaminase by rational structure-based de novo design and succeeded in the discovery of 1-(1-hydroxy-4-phenyl-2-butyl)imidazole-4-carboxamide (FR221647: K(i)=5.9 microM to human ADA) as a novel inhibitor with moderate activity and good pharmacokinetics compared with the known inhibitors pentostatin and EHNA. Pentostatin 342-353 adenosine deaminase Homo sapiens 232-235 14630704-5 2004 The ability of ecto-ADA to inhibit the cAMP response was demonstrated by treatment with the specific ADA inhibitor 2"-deoxycoformycin. Pentostatin 115-133 adenosine deaminase Homo sapiens 15-23 14630704-5 2004 The ability of ecto-ADA to inhibit the cAMP response was demonstrated by treatment with the specific ADA inhibitor 2"-deoxycoformycin. Pentostatin 115-133 adenosine deaminase Homo sapiens 20-23 11067867-2 2000 C57BL/6 fetal thymuses treated with the specific ADA inhibitor 2"-deoxycoformycin exhibited features of the human disease, including accumulation of dATP and inhibition of S-adenosylhomocysteine hydrolase enzyme activity. Pentostatin 63-81 adenosine deaminase Homo sapiens 49-52 12150791-6 2002 The A(1) receptor agonist-induced aggregation was blocked by R-deoxycoformycin, an irreversible adenosine deaminase inhibitor. Pentostatin 61-78 adenosine deaminase Homo sapiens 96-115 12150791-8 2002 R-Deoxycoformycin treatment, which has previously been shown to block the interaction between adenosine deaminase and A(1) receptors, and which is crucial for the high-affinity state of the A(1) receptor, also blocked the A(1) receptor agonist-induced loss of high-affinity D(1) receptor binding. Pentostatin 0-17 adenosine deaminase Homo sapiens 94-113 11522446-8 2001 Pretreatment with 2"-deoxycoformycin (DCF), inhibitor of adenosine deaminase, abolished these effects of PAN on cultured GECs. Pentostatin 18-36 adenosine deaminase Homo sapiens 57-76 11522446-8 2001 Pretreatment with 2"-deoxycoformycin (DCF), inhibitor of adenosine deaminase, abolished these effects of PAN on cultured GECs. Pentostatin 38-41 adenosine deaminase Homo sapiens 57-76 12670468-1 2003 Pentostatin (2"-deoxycoformycin; Nipent), a potent inhibitor of adenosine deaminase, is a purine nucleoside analogue that is highly effective in the treatment of hairy-cell leukemia. Pentostatin 0-11 adenosine deaminase Homo sapiens 64-83 12670468-1 2003 Pentostatin (2"-deoxycoformycin; Nipent), a potent inhibitor of adenosine deaminase, is a purine nucleoside analogue that is highly effective in the treatment of hairy-cell leukemia. Pentostatin 13-31 adenosine deaminase Homo sapiens 64-83 12670468-1 2003 Pentostatin (2"-deoxycoformycin; Nipent), a potent inhibitor of adenosine deaminase, is a purine nucleoside analogue that is highly effective in the treatment of hairy-cell leukemia. Pentostatin 33-39 adenosine deaminase Homo sapiens 64-83 10926348-3 2000 Cytarabine is principally active in the S phase of the cell cycle and is most toxic to replicating cells, whereas pentostatin, fludarabine and cladribine are incorporated into DNA during the process in which strand breaks are repaired and are therefore cytotoxic to slowly replicating cells (although the action of pentostatin results from its inhibition of adenosine deaminase). Pentostatin 114-125 adenosine deaminase Homo sapiens 358-377 10488704-4 1999 METHODS: Whole blood from 17 patients and 17 healthy controls stimulated with lipopolysaccharide was cultured in the presence of adenosine at different concentrations and, in some experiments, with the adenosine deaminase inhibitor deoxycoformycin. Pentostatin 232-247 adenosine deaminase Homo sapiens 202-221 10887640-5 2000 This trial will evaluate the effect of pentostatin (Nipent), a potent adenosine deaminase inhibitor with known efficacy against T-cell malignancies, on relapsed/refractory T-cell lymphomas in relation to CD26 expression. Pentostatin 39-50 adenosine deaminase Homo sapiens 70-89 10887640-5 2000 This trial will evaluate the effect of pentostatin (Nipent), a potent adenosine deaminase inhibitor with known efficacy against T-cell malignancies, on relapsed/refractory T-cell lymphomas in relation to CD26 expression. Pentostatin 52-58 adenosine deaminase Homo sapiens 70-89 10488704-8 1999 To test the hypothesis that plasma adenosine deaminase, which was increased in the patients" plasma, was actually involved in this blunted response to adenosine in alcoholic cirrhosis, we performed adenosine dose-response experiments and pharmacologically blocked adenosine deaminase activity with deoxycoformycin. Pentostatin 298-313 adenosine deaminase Homo sapiens 35-54 9495239-1 1998 We have assessed the intracellular metabolism of 2"-deoxyadenosine in a human colon-carcinoma cell line (LoVo), both in the absence and in the presence of deoxycoformycin, the powerful inhibitor of adenosine deaminase. Pentostatin 155-170 adenosine deaminase Homo sapiens 198-217 9342431-10 1997 Pentostatin also resulted in a significant reduction in the accumulation of inosine and hypoxanthine, indicating inhibition of adenosine deaminase activity. Pentostatin 0-11 adenosine deaminase Homo sapiens 127-146 7733907-0 1995 Mutagenesis of human adenosine deaminase to active forms that partially resist inhibition by pentostatin. Pentostatin 93-104 adenosine deaminase Homo sapiens 21-40 8846128-3 1996 2"-deoxycoformycin (2"-dCF) is an inhibitor of adenosine deaminase (ADA) and is toxic to lymphocytes and monocytes. Pentostatin 0-18 adenosine deaminase Homo sapiens 47-66 8846128-3 1996 2"-deoxycoformycin (2"-dCF) is an inhibitor of adenosine deaminase (ADA) and is toxic to lymphocytes and monocytes. Pentostatin 0-18 adenosine deaminase Homo sapiens 68-71 8846128-3 1996 2"-deoxycoformycin (2"-dCF) is an inhibitor of adenosine deaminase (ADA) and is toxic to lymphocytes and monocytes. Pentostatin 20-26 adenosine deaminase Homo sapiens 47-66 8846128-3 1996 2"-deoxycoformycin (2"-dCF) is an inhibitor of adenosine deaminase (ADA) and is toxic to lymphocytes and monocytes. Pentostatin 20-26 adenosine deaminase Homo sapiens 68-71 9010576-1 1996 The observation of lymphopenia in children deficient in adenosine deaminase (ADA) led to exploration of an inhibitor of the enzyme in lymphoid malignancies; thus deoxycoformycin was the first purine nucleotide used in human trials. Pentostatin 162-177 adenosine deaminase Homo sapiens 56-75 9010576-1 1996 The observation of lymphopenia in children deficient in adenosine deaminase (ADA) led to exploration of an inhibitor of the enzyme in lymphoid malignancies; thus deoxycoformycin was the first purine nucleotide used in human trials. Pentostatin 162-177 adenosine deaminase Homo sapiens 77-80 14651224-5 1996 It was anticipated that pentostatin would be most active in neoplasms with high intracellular concentrations of ADA, e.g. acute lymphocytic leukemia (ALL), particularly of the T-cell variety. Pentostatin 24-35 adenosine deaminase Homo sapiens 112-115 14651224-7 1996 By contrast, pentostatin proved to be exceptionally active in hairy cell leukemia (HCL), a B-cell neoplasm with low intracellular concentrations of ADA. Pentostatin 13-24 adenosine deaminase Homo sapiens 148-151 9204061-2 1997 Pentostatin is a potent inhibitor of adenosine deaminase and is selectively toxic to lymphocytes. Pentostatin 0-11 adenosine deaminase Homo sapiens 37-56 9022297-1 1996 Human lymphocytes lacking adenosine deaminase die and T-cell leukemias are killed by deoxycoformycin (dCf), an inhibitor of adenosine deaminase, due to impaired metabolism of dAdo. Pentostatin 85-100 adenosine deaminase Homo sapiens 124-143 9022297-1 1996 Human lymphocytes lacking adenosine deaminase die and T-cell leukemias are killed by deoxycoformycin (dCf), an inhibitor of adenosine deaminase, due to impaired metabolism of dAdo. Pentostatin 102-105 adenosine deaminase Homo sapiens 26-45 9022297-1 1996 Human lymphocytes lacking adenosine deaminase die and T-cell leukemias are killed by deoxycoformycin (dCf), an inhibitor of adenosine deaminase, due to impaired metabolism of dAdo. Pentostatin 102-105 adenosine deaminase Homo sapiens 124-143 8590388-6 1995 In contrast with reports on 2"-deoxycoformycin (Cooney et al., 1987), the adenosine deaminase inhibitors tested by us showed a significant increase in the antiviral activity of ddAdo, but not of ddIno. Pentostatin 28-46 adenosine deaminase Homo sapiens 74-93 7733907-1 1995 Human adenosine deaminase (ADA) cDNA was randomly mutagenized in vitro and bacterial transformants were selected for resistance to the potent enzyme inhibitor, pentostatin (dCF). Pentostatin 160-171 adenosine deaminase Homo sapiens 6-25 7733907-1 1995 Human adenosine deaminase (ADA) cDNA was randomly mutagenized in vitro and bacterial transformants were selected for resistance to the potent enzyme inhibitor, pentostatin (dCF). Pentostatin 160-171 adenosine deaminase Homo sapiens 27-30 7733907-1 1995 Human adenosine deaminase (ADA) cDNA was randomly mutagenized in vitro and bacterial transformants were selected for resistance to the potent enzyme inhibitor, pentostatin (dCF). Pentostatin 173-176 adenosine deaminase Homo sapiens 6-25 7733907-1 1995 Human adenosine deaminase (ADA) cDNA was randomly mutagenized in vitro and bacterial transformants were selected for resistance to the potent enzyme inhibitor, pentostatin (dCF). Pentostatin 173-176 adenosine deaminase Homo sapiens 27-30 7733907-2 1995 Cells transformed with mutant plasmids dCF-R2 and dCF-R6 were able to grow in the presence of 10(-6) M dCF, whereas 10(-11) M dCF blocked growth of cells complemented with wild-type ADA. Pentostatin 39-42 adenosine deaminase Homo sapiens 182-185 7733907-2 1995 Cells transformed with mutant plasmids dCF-R2 and dCF-R6 were able to grow in the presence of 10(-6) M dCF, whereas 10(-11) M dCF blocked growth of cells complemented with wild-type ADA. Pentostatin 50-53 adenosine deaminase Homo sapiens 182-185 1504408-0 1992 Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Pentostatin 0-11 adenosine deaminase Homo sapiens 16-35 11847552-5 1995 It was anticipated that pentostatin would be most active in neoplasms with high intracellular concentrations of ADA---e.g., acute lymphocytic leukemia (ALL), particularly its T cell variety. Pentostatin 24-35 adenosine deaminase Homo sapiens 112-115 11847552-7 1995 By contrast, pentostatin proved to be exceptionally active in hairy cell leukemia (HCL), a B cell neoplasm with low intracellular concentrations of ADA. Pentostatin 13-24 adenosine deaminase Homo sapiens 148-151 7506651-2 1993 Pentostatin, a potent inhibitor of adenosine deaminase, is an antineoplastic agent which has been studied in the treatment of a variety of lymphoproliferative disorders. Pentostatin 0-11 adenosine deaminase Homo sapiens 35-54 8408919-3 1993 Elevated adenosine deaminase activity in T cell leukemia has been reported, and its inhibitor, deoxycoformycin, has been developed as an antitumor agent. Pentostatin 95-110 adenosine deaminase Homo sapiens 9-28 1449110-3 1992 2"-Deoxycoformycin is an inhibitor of adenosine deaminase (ADA), an enzyme found in relatively high amounts in malignant lymphoid cells. Pentostatin 0-18 adenosine deaminase Homo sapiens 38-57 1449110-3 1992 2"-Deoxycoformycin is an inhibitor of adenosine deaminase (ADA), an enzyme found in relatively high amounts in malignant lymphoid cells. Pentostatin 0-18 adenosine deaminase Homo sapiens 59-62 7525186-6 1994 The purine analogues fludarabine and cladribine (2-chloro-2"-deoxyadenosine) and the adenosine deaminase inhibitor deoxycoformycin all have therapeutic effects in a range of lymphoproliferative disorders. Pentostatin 115-130 adenosine deaminase Homo sapiens 85-104 1490883-1 1992 A practical process is described for the large-scale isolation of pentostatin, an adenosine deaminase inhibitor used clinically for the treatment of interferon-refractory hairy cell leukemia. Pentostatin 66-77 adenosine deaminase Homo sapiens 82-101 1504093-1 1992 Several adenosine analogs, such as coformycin, 2"-deoxycoformycin and erythro-9-(3-nonyl-p-aminobenzyl)adenine (EHNA), which are strong inhibitors of mammalian adenosine deaminase, are much weaker inhibitors of the Saccharomyces cerevisiae enzyme. Pentostatin 47-65 adenosine deaminase Homo sapiens 160-179 1528066-1 1992 The leukemic cells of a patient with CD4+ prolymphocytic leukemia were treated in vitro with 5 microM deoxyadenosine and 60 microM 2"-deoxycoformycin (dCF), an inhibitor of adenosine deaminase (ADA). Pentostatin 131-149 adenosine deaminase Homo sapiens 173-192 1504408-11 1992 CONCLUSIONS: Pentostatin is a purine analog that inhibits adenosine deaminase, a key enzyme necessary for purine salvage. Pentostatin 13-24 adenosine deaminase Homo sapiens 58-77